Ask HopeStage to review this study with me
Study reference: NCT07002684. HopeStage can help you review the study, but cannot decide medical eligibility.
RecruitingNCT07002684
Metabolic Profiling of Esketamine Treatment in Depressive Disorder
This study is recruiting. It focuses on depression and currently lists participation information in Croatia.
DepressionDrugFrom 18 Years to 70 Years
Key information made simple
This observational study is following people with depression to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.
Your next step
The official record suggests in-person participation through a research setting, with sites including Tea Fabijanić in Zagreb. Participation appears to center on questionnaires, assessments, or follow-up information rather than a study treatment. The main fit is usually meeting the main study requirements and having a stable enough treatment background for the study, while common reasons not to take part include active substance or alcohol problems that could affect the results and pregnancy or breastfeeding. The official record does not list a trial phase, which usually means the study is focused on observation rather than testing a staged treatment.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: April 1, 2023
- Time commitment
- long follow-up or multiple visits
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Recruiting
- Sponsor
- University of Zagreb
- Sponsor type
- University
- Main activity
- medication or study treatment
- Intervention
- Not available
- Source
- Official registry link
Want help reviewing this study?
Key study information
- Condition
- Depression
- Study status
- Recruiting
- Sponsor / lead affiliation
- University of Zagreb
- Location / country
- Croatia
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT07002684
Why this study may matter
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Croatia.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT07002684
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is Metabolic Profiling of Esketamine Treatment in Depressive Disorder?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by University of Zagreb. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meOther studies you may want to explore next
RecruitingNCT06578845
HappyMums Mobile Application Study
This study is recruiting. It focuses on depression and currently lists participation information in Croatia, Finland, Germany, Italy, Poland, and the United Kingdom.
RecruitingNCT06966401
NBI-1065845 for depression
This study is recruiting in the United States, in the United Kingdom, in Belgium, .... It is testing NBI-1065845 for depression.
RecruitingISRCTN12329547
study of a digital depression management application: juli
This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom, Afghanistan, Finland, Albania, Algeria, the United States, Andorra, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, the Netherlands, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Norway, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Congo, Democratic Republic, New Zealand, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Vatican City, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, North Korea, South Korea, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Federated States of, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Macedonia, Oman, Pakistan, Palau, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, the Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkmenistan, Tuvalu, Turkey, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Western Sahara, Yemen, Zambia, and Zimbabwe.